Comparison · NCT01023217-8128873d
Adefovir Plus Entecavir vs Adefovir Plus Lamivudine: Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adefovir Plus Entecavir vs Adefovir Plus Lamivudine: Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL). Trial comparisons, record NCT01023217-8128873d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01023217-8128873d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.289 | 0.177 | 0.434 | wilson | |
| Risk in group 2 | 0.0444 | 0.0123 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | 0.244 | 0.092 | 0.393 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.5 | 1.56 | 27.2 | log | |
| Odds ratio, group 1 over group 2 | 8.73 | 1.84 | 41.5 | log | |
| Number needed to treat, for one more participant with the outcome on Adefovir Plus Entecavir than on Adefovir Plus Lamivudine | 4.09 | 2.55 | 10.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adefovir Plus Entecavir | Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks~Adefovir plus Entecavir: Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks | 13 | 45 | OG000 |
| Group 2 | Adefovir Plus Lamivudine | Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks~Adefovir plus Lamivudine: Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks | 2 | 45 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
- Description
- Time frame
- at week 52 from randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
- NCT number
- NCT01023217
- Phases
- PHASE4
- Conditions
- Hepatitis B, Chronic
- Interventions
- Adefovir, Entecavir, Lamivudine
- Lead sponsor
- Asan Medical Center
- Results first posted
- 2014-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01023217?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01023217-8128873d